Clarus Wins Patent Infringement Lawsuit Brought By Lipocine On JATENZO

US District Court for the District of Delaware has granted Clarus Therapeutics' motion for summary judgment against remaining patents in patent infringement case brought by Lipocine Inc. (LPCN) regarding Clarus's oral testosterone replacement product JATENZO.

Federal Circuit Judge William Bryson, a Senior Circuit Judge of the U.S. Court of Appeals for the Federal Circuit, sitting by designation in the U.S. District Court for the District of Delaware found all of the asserted Lipocine patent claims invalid.

Clarus's defense of inequitable conduct, to be tried before Judge Bryson, remains pending, and its disposition is expected to be addressed by Clarus and the Court at a future date.

The action for patent infringement was brought by Lipocine against Clarus on April 2, 2019, arising out of Clarus's marketing of JATENZO, an oral testosterone replacement product approved by the FDA in March of 2019, and launched in March of 2020.

Lipocine previously dismissed infringement allegations against Clarus on two other Lipocine patents.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT